Cargando…

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor

Pancreatitis is rare in pancreatic insufficient cystic fibrosis patients. While pancreatic insufficiency has been considered irreversible until now, in the current era of new therapies with modulators of the Cystic Fibrosis Transmembrane Regulator CFTR channel, there are reports of improvement of pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrocheilou, Argyri, Kaditis, Athanasios G., Loukou, Ioanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022767/ https://www.ncbi.nlm.nih.gov/pubmed/31940891 http://dx.doi.org/10.3390/children7010006

Ejemplares similares

Nebulizer Care and Inhalation Technique in Children with Cystic Fibrosis
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Early-Life Pseudomonas aeruginosa Infection in Cystic Fibrosis and Lung Disease Progression
por: Petrocheilou, Argyri, et al.
Publicado: (2017)

Inflammation and Infection in Cystic Fibrosis: Update for the Clinician
por: Petrocheilou, Argyri, et al.
Publicado: (2022)

Impact of COVID-19 Lockdown on Pulmonary and Nutritional Status in Children and Young Adults With Cystic Fibrosis, in Greece
por: Loukou, Ioanna, et al.
Publicado: (2021)

Triage for Malnutrition Risk among Pediatric and Adolescent Outpatients with Cystic Fibrosis, Using a Disease-Specific Tool
por: Poulimeneas, Dimitrios, et al.
Publicado: (2020)

Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019
por: Stathi, Angeliki, et al.
Publicado: (2019)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
por: Kapouni, Nikoletta, et al.
Publicado: (2023)

Adherence to Dietary Recommendations, Nutrient Intake Adequacy and Diet Quality among Pediatric Cystic Fibrosis Patients: Results from the GreeCF Study
por: Poulimeneas, Dimitrios, et al.
Publicado: (2020)

Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio)
por: Salehi, Mahan, et al.
Publicado: (2021)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes
por: Christian, Francis, et al.
Publicado: (2019)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor
por: Patel, Payal, et al.
Publicado: (2023)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Acute Pancreatitis in a Previously Exocrine Pancreatic Insufficient Cystic Fibrosis Patient Who Had Improved Pancreatic Function After Being Treated With Lumacaftor/Ivacaftor
por: Redman, Alexander W., et al.
Publicado: (2021)

Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation
por: Wood, Michelle E, et al.
Publicado: (2013)

Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis
por: Orsini, Sara Immacolata, et al.
Publicado: (2023)

Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Moustaki, Maria, et al.
Publicado: (2017)

Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis
por: Stekolchik, Elena, et al.
Publicado: (2022)

Ivacaftor: Five‐year outcomes in the West of Scotland cystic fibrosis population
por: Al‐Din, Yasmin, et al.
Publicado: (2023)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving Elexacaftor-Tezacaftor-Ivacaftor
por: Balmpouzis, Zisis, et al.
Publicado: (2022)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Effect of Ivacaftor on Objective and Subjective Measures of Cough in Patients with Cystic Fibrosis
por: Faruqi, Shoaib, et al.
Publicado: (2016)

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
por: Neerincx, Anne H., et al.
Publicado: (2021)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
por: O’Reilly, Ruth, et al.
Publicado: (2013)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis
por: Goldberg, Rebecca H., et al.
Publicado: (2021)

Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E
por: Salvatore, Donatello, et al.
Publicado: (2021)

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience
por: Higgins, Mark, et al.
Publicado: (2020)

The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
por: Lommatzsch, Sherstin T., et al.
Publicado: (2019)

Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101K with end-stage lung disease
por: Leung, Winnie M., et al.
Publicado: (2023)

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients
por: Gostelie, Romee, et al.
Publicado: (2020)

Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
por: Kutney, Katherine, et al.
Publicado: (2019)

THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
por: MILES, B., et al.
Publicado: (2022)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k6s98gt17d2roc9m1h2l8lt24h